Successful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimony

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 39, Issue 4, 2006, Pages 376-378

  De Oliveira Neto, Manoel Paes ^a   Mattos, Marise Da Silva ^a,b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b NONE   (United States)

Author keywords

Antimony; Low dose; Mucocutaneous leishmaniasis; Therapy resistance

Indexed keywords

AMPHOTERICIN B; MEGLUMINE ANTIMONATE; PENTAMIDINE;

ABSENCE OF SIDE EFFECTS; ADULT; AMASTIGOTE; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LOW DRUG DOSE; MALE; SKIN LEISHMANIASIS;

EID: 33749163229     PISSN: 00378682     EISSN: 00378682     Source Type: Journal    
DOI: 10.1590/s0037-86822006000400011     Document Type: Article

References (17)

1. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 72:133-137, 2005.
2. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical of Infectious Diseases 24:684-703, 1997.
3. Cachia EA, Fenech FF. A review of kala-azar in Malta from 1947 to 1962. Transaction of Royal Society of Tropical Medicine and Hygiene 58:234-241, 1964.
4. Croft SL, Coombs GH. Leishmaniasis current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitology 19:502-508, 2003.
5. De Azeredo-Coutinho RB, Mendonça SC. An intermittent Schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 35:477-481, 2002.
6. Falcoff E, Taranto NJ, Remondegui CE, Dedet JP, Canini LM, Ripoll CM, Dimier-David L, Vargas F, Gimenez LA, Bernarbo JG. Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-γ and pentavalent antimonial compounds. Transactions of Royal Society of Tropical Medicine and Hygiene 88:95-97, 1994.
7. Grimaldi Jr G, Tesh RB. Leishmaniasis of the New World: current concepts and implications for future research. Clinical Microbiology Reviews 6:230-250, 1993.
8. Marsden PD, Sampaio RN, Carvalho EM, Veiga JP, Costa JL, Llanos-Cuentas EA. High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. The American Journal of Tropical Medicine and Hygiene 34: 710-713, 1985.
9. Mattos M. Determinação de parâmetros clínicos e prognósticos para o controle de cura da leishmaniose tegumentar americana. Tese de Doutorado. Fundação Oswaldo Cruz, Rio de Janeiro, RJ, 2004.
10. Oliveira-Neto MP, Schubach A, Araujo ML, Pirmez C. High and low doses of antimony in American cutaneous leishmaniasis. A five years follow-up study of 15 patients. Memórias do Instituto Oswaldo Cruz 91:207-209, 1996.
11. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. International Journal of Dermatology 76:463-468, 1997.
12. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. A low dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). The American Journal of Tropical Medicine and Hygiene 57:651-655, 1997.
13. Oliveira-Neto MP, Mattos M, Pirmez C, Fernandes O, Gonçalves-Costa SC, Souza CF, Grimaldi Jr G. Mucosal leishmaniasis (espundia) responsive to low dose of N-methyl glucamine in Rio de Janeiro. Revista do Instituto de Medicina Tropical de São Paulo 42:321-325, 2000.
14. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to Leishmania (Viannia) species. The American Journal of Tropical Medicine and Hygiene 64:187-193, 2001.
15. Schubach AO, Marzochi KBF, Moreira JS, Schubach TMP, Pacheco TM, Araújo, ML, Vale ACF, Passos SRL, Marzochi MCA. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Revista da Sociedade Brasileira de Medicina Tropical 38:213-217, 2005.
16. Soto J, Toledo J, Vega J, Berman J. Short report: efficacy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 72:421-422, 2005.
17. Vargas-Gonzales A, Canto-Lara SB, Damian-Centeno AG, Andrade-Narvaez FG. Response of cutaneous (chiclero's ulcer) to treatment with meglumine antimoniate in south-east México. The American Journal of Tropical Medicine and Hygiene 61:960-963, 1999.